Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres

Haematologica

Volumn 100, Issue 10, 2015, Pages 1267-1274

  Bär, Christian ^a   Huber, Nicolas ^a   Beier, Fabian ^a,b   Blasco, Maria A ^a  

^a Structural Biology and Biocomputing Programme   (Spain)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; ESTRADIOL; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERIC REPEAT BINDING FACTOR 1; TESTOSTERONE; ANDROGEN; MESSENGER RNA; TELOMERASE; TERT PROTEIN, MOUSE;

ANDROGEN THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APLASTIC ANEMIA; ARTICLE; BLOOD ANALYSIS; BONE MARROW CELL; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE SHORTENING; UPREGULATION; ANEMIA, APLASTIC; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MORTALITY; TRANSGENIC MOUSE;

ANDROGENS; ANEMIA, APLASTIC; ANIMALS; BONE MARROW CELLS; DISEASE MODELS, ANIMAL; ESTRADIOL; FIBROBLASTS; GENE EXPRESSION; HUMANS; MICE; MICE, TRANSGENIC; RNA, MESSENGER; TELOMERASE; TELOMERE SHORTENING; TESTOSTERONE;

EID: 84943255698     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2015.129239     Document Type: Article

References (39)

1. Dolberg OJ, Levy Y. Idiopathic aplastic anemia: diagnosis and classification. Autoimmun Rev. 2014;13(4 5):569-573.
2. Nakao S. Immune mechanism of aplastic anemia. Int J Hematol. 1997;66(2):127-134.
3. Dokal I, Vulliamy T. Inherited bone marrow failure syndromes. Haematologica. 2010;95 (8):1236-1240.
4. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106(6):661-673.
5. de Lange T. Shelterin: the protein complex that shapes and safeguards human telom-eres. Genes Dev. 2005;19(18):2100-2110.
6. Schaetzlein S, Lucas-Hahn A, Lemme E, et al. Telomere length is reset during early mammalian embryogenesis. Proc Natl Acad Sci USA. 2004;101(21):8034-8038.
7. Varela E, Schneider RP, Ortega S, Blasco MA. Different telomere-length dynamics at the inner cell mass versus established embryonic stem (ES) cells. Proc Natl Acad Sci USA. 2011;108(37):15207-15212.
8. Vera E, Bernardes de Jesus B, Foronda M, Flores JM, Blasco MA. The rate of increase of short telomeres predicts longevity in mammals. Cell Rep. 2012;2(4):732-737.
9. Flores I, Canela A, Vera E, Tejera A, Cotsarelis G, Blasco MA. The longest telom-eres: a general signature of adult stem cell compartments. Genes Dev. 2008;22(5):654-667.
10. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-460.
11. Canela A, Vera E, Klatt P, Blasco MA. High-throughput telomere length quantification by FISH and its application to human population studies. Proc Natl Acad Sci USA. 2007;104(13):5300-5305.
12. Hiyama E, Hiyama K. Telomere and telom-erase in stem cells. Br J Cancer. 2007;96(7): 1020-1024.
13. Vulliamy T, Marrone A, Dokal I, Mason PJ. Association between aplastic anaemia and mutations in telomerase RNA. Lancet. 2002;359(9324):2168-2170.
14. Savage SA, Alter BP. Dyskeratosis congenita. Hematol Oncol Clin North Am. 2009;23(2):215-231.
15. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-2365.
16. de la Fuente J, Dokal I. Dyskeratosis con-genita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant. 2007;11(6):584-594.
17. Marsh JC, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70.
18. Shahidi NT, Diamond LK. Testosterone-induced remission in aplastic anemia of both acquired and congenital types. Further observations in 24 cases. N Engl J Med. 1961;264:953-967.
19. Jaime-Perez JC, Colunga-Pedraza PR, Gomez-Ramirez CD, et al. Danazol as first-line therapy for aplastic anemia. Ann Hematol. 2011;90(5):523-527.
20. Kyo S, Takakura M, Kanaya T, et al. Estrogen activates telomerase. Cancer Res. 1999;59(23):5917-5921.
21. Calado RT, Yewdell WT, Wilkerson KL, et al. Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood. 2009;114 (11):2236-2243.
22. Beier F, Foronda M, Martinez P, Blasco MA. Conditional TRF1 knockout in the hematopoietic compartment leads to bone marrow failure and recapitulates clinical features of dyskeratosis congenita. Blood. 2012(15) 2990-3000.
23. Deng Y, Chan SS, Chang S. Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer. 2008;8 (6):450-458.
24. Martinez P, Thanasoula M, Munoz P, et al. Increased telomere fragility and fusions resulting from TRF1 deficiency lead to degenerative pathologies and increased cancer in mice. Genes Dev. 2009;23(17):2060-2075.
25. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. J Cell Biol. 1963;17 299-313.
26. Xu J. Preparation, culture, and immortalization of mouse embryonic fibroblasts. Curr Protoc Mol Biol. 2005;Chapter 28(28): 21.
27. Samper E, Goytisolo FA, Slijepcevic P, van Buul PP, Blasco MA. Mammalian Ku86 protein prevents telomeric fusions independently of the length of TTAGGG repeats and the G-strand overhang. EMBO Rep. 2000;1(3):244-252.
28. Canela A, Klatt P, Blasco MA. Telomere length analysis. Methods Mol Biol. 2007; 371:45-72.
29. Liu Y, Snow BE, Hande MP, et al. The telom-erase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biol. 2000;10(22):1459-1462.
30. Petz LN, Ziegler YS, Schultz JR, Kim H, Kemper JK, Nardulli AM. Differential regulation of the human progesterone receptor gene through an estrogen response element half site and Sp1 sites. J Steroid Biochem Mol Biol. 2004;88(2):113-122.
31. Porter W, Wang F, Wang W, Duan R, Safe S. Role of estrogen receptor/Sp1 complexes in estrogen-induced heat shock protein 27 gene expression. Mol Endocrinol. 1996;10(11): 1371-1378.
32. Gurney CW, Fried W. Further studies on the erythropoietic effect of androgens. J Lab Clin Med. 1965;65 775-782.
33. Fried W, Gurney CW. The erythropoietic-stimulating effects of androgens. Ann N Y Acad Sci. 1968;149(1):356-365.
34. Zhao Y, Sfeir AJ, Zou Y, et al. Telomere extension occurs at most chromosome ends and is uncoupled from fill-in in human cancer cells. Cell. 2009;138(3):463-475.
35. Marcand S, Brevet V, Mann C, Gilson E. Cell cycle restriction of telomere elongation. Curr Biol. 2000;10(8):487-490.
36. Gardner FH. Androgen therapy of aplastic anaemia. Clin Haematol. 1978;7(3):571-585.
37. Champlin RE, Ho WG, Feig SA, Winston DJ, Lenarsky C, Gale RP. Do androgens enhance the response to antithymocyte globulin in patients with aplastic anemia? A prospective randomized trial. Blood. 1985;66(1):184-188.
38. Dokal I, Vulliamy T. Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev. 2008;22(3):141-153.
39. Franco S, van de Vrugt HJ, Fernandez P, Aracil M, Arwert F, Blasco MA. Telomere dynamics in Fancg-deficient mouse and human cells. Blood. 2004;104(13):3927-3935.